|
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910818706103321 |
|
|
Titolo |
International benchmarking of US immunology research / / Panel on International Benchmarking of US Immunology Research, Committee on Science, Engineering, and Public Policy, National Academy of Sciences, National Academy of Engineering, Institute of Medicine |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Washington, DC, : National Academy Press, 1999 |
|
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (60 pages) : illustrations |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Immunology - Research |
Immunity |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
""INTERNATIONAL BENCHMARKING OF US IMMUNOLOGY RESEARCH""; ""Copyright""; ""PREFACE""; ""CONTENTS""; ""EXECUTIVE SUMMARY""; ""1 INTRODUCTION""; ""1.1 HOW IMPORTANT IS IT FOR THE UNITED STATES TO LEAD IN IMMUNOLOGY RESEARCH?""; ""1.2 WHAT IS IMMUNOLOGY?""; ""1.3 IMMUNOLOGY AS AN ACADEMIC DISCIPLINE""; ""1.4 WHAT IS THE INTERNATIONAL NATURE OF IMMUNOLOGY?""; ""1.5 WHAT ARE SOME CAVEATS?""; ""1.6 PANEL CHARGE AND RATIONALE""; ""2 BENCHMARKING RESULTS""; ""2.1 METHODS""; ""2.1.1 Reputation Survey""; ""2.1.2 Citation Analysis""; ""2.1.3 Journal Publication Analysis""; ""2.2 RESULTS"" |
""2.2.1 Reputation Survey"" ""2.2.2 Citation Analysis""; ""2.2.3 Journal Publication Analysis""; ""2.3 SUMMARY""; ""3 KEY FACTORS""; ""3.1 FUNDING""; ""3.2 HUMAN RESOURCES""; ""3.3 INFRASTRUCTURE""; ""3.4 BIOTECHNOLOGY AND PHARMACEUTICAL FIRMS""; ""3.5 THE CLINICAL TRIAL""; ""4 LIKELY FUTURE POSITION""; ""4.1 FUNDING AND RESOURCE LIMITATIONS""; ""4.2 INCREASED COMPETITION FROM EUROPE AND OTHER COUNTRIES""; ""4.3 CLINICAL IMMUNOLOGY AND THE SHIFT TOWARD HMOS""; ""4.4 TRAINING OF US STUDENTS""; ""5 SUMMARY AND CONCLUSIONS"" |
""5.1 THE UNITED STATES IS THE WORLD LEADER IN ALL THE MAJOR SUBFIELDS OF IMMUNOLOGY BUT IS ONLY AMONG THE WORLD LEADERS |
|
|
|
|
|
|
|
|
|
|
IN""""5.2 FLEXIBILITY TO PURSUE ORIGINAL AND INNOVATIVE RESEARCH IDEAS HAS ATTRACTED BOTH DOMESTIC AND INTERNATIONAL HUMAN""; ""5.3 INDUSTRIAL INTERESTS HAVE FOSTERED MANY STRIKING BREAKTHROUGHS IN IMMUNOLOGY""; ""5.4 A SCARCITY OF LARGE-SCALE CLINICAL TRIALS IN IMMUNOLOGY CAN BE ATTRIBUTED TO SHORTAGES OF FUNDING AND OF QUALIFIED""; ""5.5 SHIFTING FEDERAL AND INDUSTRY PRIORITIES, A POTENTIAL REDUCTION IN ACCESS TO DOMESTIC AND FOREIGN TALENT, AND THE""; ""REFERENCES""""APPENDIX PANEL AND STAFF BIOGRAPHICAL INFORMATION""; ""STAFF"" |
|
|
|
|
|
| |